The stock of Atossa Therapeutics, Inc. (NASDAQ:ATOS) is now priced at $2.51 and the shares are -0.04 points down or -1.57% lower compared to its previous closing price of $2.55. The stock had 1.072 million contracts set over the past session. ATOS shares’ daily volume is compared to its average trading volume at 833138 shares. However, it has a float of 10.37 million and although its performance was -18.77% over the week, it’s one to watch. It means the stock’s downside potential is -100% with the ATOS share price recently placing at $2.36 to $2.95. However, some brokerage firms have priced the stock below the average, including one that has called $8.

The shorts are climbing into the Atossa Therapeutics, Inc. stock, with the latest data on short interest released on August 14, 2020, showing that short interest numbers in the ATOS shares have risen. Short interest in the stock represents just 2.46% of its float, but the volume has raised by 77369. The volume of shorted shares rised to 255528 from 178159 shares over the last two weeks. The average intraday trading volume has been 761281 shares, which means that days to cover moved to roughly 1.

In the last trading session, Atossa Therapeutics, Inc. (NASDAQ:ATOS) dropped by -$0.58 over the week and lost -$1.36 on its 20-day. The stock’s high in the recent session is lower when compared to its 52-week high of $5.08. The stock recorded its established 52-week high on 08/03/20.

Since 03/12/20, the stock has traded to a low of $0.75 at 232.45%, an encouraging piece of data likely to interest most investors out to exploit the stock’s recent surge. The stock has a beta allocation of 2.32. Being above 1 means that the stock’s volatility is higher than the market and traders are keenly watching it.

Looking at current readings, Atossa Therapeutics, Inc.’s two-week RSI is 29.8. This suggests that the stock is overbought at the moment and that ATOS shares’ price movement remains not stable. The stochastic readings are equally revealing at 7.41% meaning the ATOS share price is currently in overbought territory.

The technical chart shows that the ATOS stock will likely settle at between $2.85 and $3.2 per share. However, if the stock dips below $2.26, then its market would become much weaker. Any downside could see the stock price sliding to levels as low as $2.02.

Currently, the stock is trading in the red of MACD, with a reading of -0.34. Investors always pay attention to any move above or below the zero-line, mainly because the indicator points to the position of the stock’s short-term average relative to its long-term measure. A MACD -a reading above the zero line means that the short-term is above the long-term average. This scenario implies that there is an upward momentum. The opposite is true when the MACD falls below the zero-line.

Analysts at Maxim Group assigned ATOS a rating of Buy in their intiating review released on January 26.

The average rating for the ATOS equity is 2 and is currently gathering a bullish momentum. Of 1 analysts tracking Atossa Therapeutics, Inc. polled by Reuters, 0 rated ATOS as a hold. The remaining 1 analysts were split evenly. However, the split wasn’t equal as a majority (1) rated it as a buy or strong buy. 0 analyst advised investors against buying the stock or to sell if they own any of the stock.